The aim is to make a systematic review of the literature to assess the effect of lipid-lowering drugs on venous thromboembolism (VTE) occurrence.
Introduction
Lipid-lowering drugs are a wide group of molecules including the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), fibrates, cholesterol absorption inhibitors, bile acid sequestrants, niacin, and fish oil. They are widely used in the management of patients with hyperlipidaemia and in the primary and secondary prevention of atherosclerotic disease. 1 Several biochemical effects have been advocated in addition to modifying lipid profile. 2 Among them, interactions with the haemostatic system and with antithrombotic drugs have been described, but the clinical relevance of these properties is still unclear. 3 Observational studies have reported a reduced risk for venous thromboembolism (VTE), i.e. deep venous thrombosis (DVT) and pulmonary embolism (PE), in patients on statins treatment and an increased risk for VTE in patients on fibrates treatment. 4 Although this effect, if true, may be associated with a modified lipid profile, the hypothesis of a clinically relevant role of lipid-lowering drugs on the coagulation system remains intriguing. 5 The primary aim of our systematic review was to assess the effect of lipid-lowering drugs, in particular statins and fibrates, on the risk of VTE.
Methods

Study identification
We attempted to identify all published studies that evaluated the effects of lipid-lowering drugs on VTE risk using the MEDLINE (1966 to April Week 1 2009) and EMBASE (1980 to April Week 2 2009) electronic databases. The following search terms (textwords and MeSH or EMTREE terms, respectively) were used for the MEDLINE search: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Anticholesteremic Agents, Clofibric Acid, Antilipemic Agents, Statins, Fibrates, Embolism and Thrombosis, Venous Thromboembolism, Vein Thrombosis; and for the EMBASE database search: Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor, Ezetimibe, Fibric Acid, Antilipemic Agent, Omega 3 Fatty Acid, Vein thrombosis, Venous Thromboembolism.
The search strategy was developed without any language restriction. Reference lists of all studies included in the present systematic review were screened for potential additional eligible studies. A letter and/or e-mail were sent to the corresponding author if the full manuscript was unavailable.
Study selection
Two authors (M.G., E.R.) independently reviewed all selected titles and abstracts. Studies were excluded if the title and/or abstract was not appropriate for the aim of our review. Full texts were subsequently obtained for eligible studies or when the relevance of an article could not be excluded with certainty. Disagreement was resolved by consensus and by opinion of a third reviewer (A.S.), if necessary. Selected studies were eligible if they met the following criteria: patients were 18 years or older and at least 100 patients were enrolled. Both observational and experimental studies were included. Reviews, casereports, and non-human studies were excluded.
Data extraction and quality assessment
For randomized controlled trials (RCTs), we planned quality assessment by means of Jadad's scale, which evaluates the following three study characteristics: method of randomization, method of blinding, and follow-up. 6 To stratify RCTs, we applied the following cut-offs: a total of five points defined high quality studies; three and four points defined medium quality studies; two or less points defined low quality studies.
Although in observational studies the use of quality scoring systems or quality scales is controversial, 7 study quality was assessed by the following items for cohort studies: type of study (prospective or retrospective); patient selection (consecutive patients without potential bias of selection); control group (consecutive enrolment or matched for age and sex). For each fulfilled item one point was given. A scoring system was adapted to identify three quality categories as follows: a total of three points defined high quality studies; two or less point defined low quality studies. The total number of patients lost to follow-up (less than 5% of patients, more than 20%, or between 5 and 20%) was also ascertained as an additional quality item. For case-control studies, the following items assessed study quality: patient selection (consecutive patients without potential bias of selection); control group (consecutive enrolment or matched for age and sex). A total of two points defined high-quality studies; one or less defined a low-quality study. The total number of cases was also ascertained as an additional quality item. One reviewer (M.G.) completed the data extraction form. A second reviewer (A.S.) checked the extracted data. The following characteristics were collected: (i) total number of enrolled patients; (ii) follow-up duration for RCTs and cohort studies; (iii) VTE diagnosis (objective or clinical); (iv) inclusion or exclusion or patients with previous VTE; (v) type of lipid-lowering drugs; (vi) molecule and dosage; (vii) use of lipid-lowering drugs for primary or secondary prevention of cardiovascular diastase; (viii) outcomes: for RCTs and cohort studies these included total VTE events, DVT, and PE; for casecontrol studies, the use of any lipid-lowering drugs. In case data were available for both current and past lipid-lowering drug use, we included in the meta-analysis only current use. Corresponding author was contacted for additional data in case absolute values were not provided in the manuscript.
Statistical analysis
Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. These data were pooled using a fixed-effects model (the MantelHaenszel method), 8 and comparing these findings with the results obtained using a random-effects model (the DerSimionan and Laird method), in particular in case of significant statistical heterogeneity. 9 In case of high statistical heterogeneity, results using random-effects model are reported. Statistical heterogeneity was evaluated using the I 2 statistic, which assesses the appropriateness of pooling the individual study results. 10 The I 2 value provides an estimate of the amount of variance across studies due to heterogeneity rather than chance. I 2 , 30%
indicates mild heterogeneity, 30-50% moderate, and .50% severe heterogeneity. When heterogeneity was present, we repeated the analysis removing one study at time to assess the source of heterogeneity. Presence of publication bias was explored using funnel plots of effect size against standard error. 
Results
Study identification and selection
We identified 1552 potentially relevant studies from the following databases: 977 from EMBASE and 575 from MEDLINE. We excluded 1526 studies after title and abstract screening using predefined inclusion and exclusion criteria; the remaining 26 studies were retrieved in full for detailed evaluation. Three additional studies were identified through manual review of references. Of the 29 retrieved studies, 15 were excluded for the following reasons: 8 did not match inclusion criteria, 5 were editorial or narrative review, and 2 reported duplicated data. 12, 13 Fourteen studies were therefore included in this systematic review. 14 -27 The study identification and selection progression is summarized in Figure 1 .
Study characteristics
Baseline characteristics of patients included in the studies were summarized in Table 1 . All studies were written in English. Studies ranged in size from 228 23 to 614 000 patients, 19 for a total of 863 805 included patients. Three RCTs, 14 -16 three cohort, 17 -19 and eight case-control studies 20 -27 were included in our systematic review. Twelve studies, i.e. one RCT, three cohort, and eight case-control studies, including 850 118 patients assessed the effect of statins on the risk of VTE. 16 -27 Three studies, i.e. two RCTs and one case -control study, including a total 15 041 patients assessed the effect of fibrates on the risk of VTE. 14, 15, 22 One of these two RCTs including 5010 patients also assessed the effect of niacin on the risk of VTE. 14 Five studies including 61 971 patients assessed, in addition to the effect of statins, the effect of lipid-lowering drugs other than statins on VTE risk without specifying which drug was used. 17, 20, 21, 25, 26 We found no studies that have assessed the effect of cholesterol absorption inhibitors, bile acid sequestrants, or fish oil on the risk of VTE.
Study quality
Quality assessment items are summarized in Table 2 . Two of the three RCTs were of high quality, but the incidence of VTE was not a primary endpoint in any of these studies. 15, 16 All three cohort studies were of low quality. Four (50%) case-control studies were of high quality. 22, 24, 26, 27 Statins The use of statins was found to significantly decrease the risk of VTE at random-effects model analysis (OR, 0.81; 95% CI, 0.66 -0.99, Figure 2 ). There was a very high heterogeneity among the studies (I 2 . 80%, P , 0.05), which was caused by the casecontrol and cohort studies. Removing one study at time, no significant modification of overall heterogeneity was identified. Among cohort studies, the study by Smeeth et al. 19 mainly contributed to statistical heterogeneity. After exploring results and heterogeneity according to study designs, no significant differences were noted in ORs and in I 2 between cohort and case-control studies ( Figure 2) . Funnel plot is shown in Figure 3 , and shows no indication of publication bias. When we pooled data from the five high-quality studies, the OR remained similar (OR, 0.75; 95% CI, 0.54-1.04, random-effects model) with a persistent high heterogeneity (I 2 .
80%). 16, 22, 24, 26, 27 Only two studies provided adequate data on the risk of PE alone 16, 24 and only three studies provided adequate data on the risk of DVT alone. 16, 17, 24 No significant differences were detected when these studies were separately analysed (at random-effects model: OR, 1.12; 95% CI, 0.63-1.99 for PE and OR, 0.72; 95% CI, 0.50-1.03 for DVT). Two studies provided data on unprovoked VTE events: at random-effects model, the OR was 0.83 (95% CI, 0.56 -1.25). 16, 27 A sensitivity analysis on potential differences among statins and on potential dosedependent effects could not be performed, because adequate data on pravastatin, rosuvastatin, and simvastatin were available in only two, one, and one studies, respectively 16, 21, 23 .
Fibrates
The use of fibrates was found to increase the risk of VTE (OR, 1.66; 95% CI, 1.35-2.04, fixed-effects model, Figure 4 ). There was no heterogeneity among the studies (I 2 ¼ 0% 
Non-statin lipid-lowering drugs
Pooling data of studies reporting the risk of VTE in non-statin lipid-lowering drugs users, we found no effect on the risk of VTE (random-effects model, OR, 0.88; 95% CI, 0.72-1.07). 17, 20, 21, 25, 26 The only study investigating niacin also failed to demonstrate an effect on the risk of VTE.
14 Discussion This is to our knowledge the first systematic review and meta-analysis that assessed the effect of lipid-lowering drugs on the risk of VTE. The results of this study indicate that the use of statins is associated with a reduced risk of VTE and that the use Statins are the best-studied and most powerful cholesterollowering drugs. 1, 28 All such properties of statins may support their potential effect also in the prevention of VTE. Based on the results of our meta-analysis including more than 850 000 patients, statins consistently reduce the risk of VTE by approximately 20%. This observation carries some important implications. First, there is now a clear need for a RCT primarily designed to evaluate the effects of statin use in patients at high risk for VTE, such as patients with previous VTE. 16, 31 Second, VTE should now be included as a clinical endpoint in all new statins trials. Third, the claimed link between atherosclerosis and VTE appears to be reinforced. 32, 33 Regardless of whether the beneficial effect of statins on the risk of VTE is simply due to lipid lowering or to their influence on thrombosis and inflammation, statins have the potential to be active on both cardiovascular and venous thromboembolic diseases.
33,34
Fibrates, peroxisome proliferator-activated receptor-a activators, have been shown in some studies to diminish the procoagulant activity and to stimulate fibrinolysis. 35 Fibrates may also increase plasma clot permeability and susceptibility to fibrinolysis in coronary artery disease patients. 35 No relevant influence on platelet function, but increased homocysteine levels, has been reported on fibrates treatment. 22, 36 Although fibrates potentially have an overall antithrombotic effect, published data suggest an increased risk for VTE. The reason for this observation remains unclear, and the increase in homocysteine levels remains the only available, albeit insufficient, explanation. 22 Well-designed in vitro and in vivo studies are thus now strongly encouraged, and also new clinical studies with fibrates should systematically include VTE events among major endpoints. The main strengths of our review include the systematic approach, the quality assessment of the literature, and the large number of patients included. Conversely, our systematic review has several potential limitations. First, our meta-analysis was almost restricted to observational studies, mainly case -control studies, and the application of formal meta-analytic methods to observational studies is controversial, since bias implicit in the study design may misrepresent the strength of associations within the data. 7, 37 However, before pooling all data together, we have provided separate analysis for cohort studies, casecontrol studies, and RCTs when available. The study design does not appear as the main reason for heterogeneity and the ORs from different study designs remain very similar. Second, studies included in our meta-analysis have different inclusion and exclusion criteria, and to combine results across studies may be inappropriate. However, when we repeated the analysis using a random-effects model, an approach that accounts for some of the variance between studies, we found similar results. Third, as an intrinsic limit of meta-analyses, our meta-analysis was by necessity restricted to single risk factors. Therefore, the distinct possibility exists that the strength of association may be weaker with a multifactorial regression analysis, given that it was not possible to adjust or stratify for potential confounders. In particular, the Figure 4 Odds ratio for the association between fibrates use and venous thromboembolism.
effect of cardiovascular risk factors and a healthy user effect should be considered. 33 Fourth, given the mean low quality of the studies included in our systematic review, our findings should be interpreted with caution. In particular, all three included RCTs had VTE as a secondary outcome only. Fifth, due to limited available published data, we cannot explore whether VTE risk reduction is a class-effect or a molecule-effect of statins. Finally, since there were too few studies evaluating the effects of fibrates, the presence of publication bias could not be evaluated. Moreover, a plausible biological rationale is lacking. However, given the magnitude of the association and the homogeneity of the results in the selected studies, it is extremely unlikely that unpublished studies with different results, if really exist, could substantially modify our findings.
In conclusion, the use of statins may reduce the risk of VTE, whereas the use of fibrates may increase this risk. Before clinical implications of our findings can be discussed, RCTs evaluating the effect of statins in patients at high risk of VTE are warranted. Future prospective studies carefully investigating the underlying mechanisms of the effects of lipid-lowering drugs on haemostasis are strongly encouraged, in particular to assess the negative effects of fibrates.
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